Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejphar.2020.173634 http://scihub22266oqcxt.onion/10.1016/j.ejphar.2020.173634 33031797!7536545!33031797     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33031797&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Eur+J+Pharmacol 2020 ; 889 (?): 173634 Nephropedia Template TP {{tp|p=33031797|t=2020. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment |pdf=|usr=}}{{33031797}} gab.com Text Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment JO: Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33031797 #FOAvip Repurposing of approved antiviral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising strategy to treat Coronavirus disease 2019 (COVID-19) patients. Previously we reported our hypothesis that the antiviral drugs with high lung distributions might benefit COVID-19 patients by reducing viral loads. So far, chloroquine, lopinavir, hydroxychloroquine, azithromycin, favipiravir, ribavirin, darunavir, remdesivir, and umifenovir have been tested in COVID-19 clinical trials. Here we validated our hypothesis by comparing the pharmacokinetics profiles of these drugs and their capabilities of reducing viral load in clinical trials. According to bulk RNA and single cell RNA sequencing analysis, we found that high expression of both angiotensin converting enzyme 2 (ACE2) and transmembrane Serine Protease 2 (TMPRSS2) makes the lung and intestine vulnerable to SARS-CoV-2. Hydroxychloroquine, chloroquine, and favipiravir, which were highly distributed to the lung, were reported to reduce viral loads in respiratory tract of COVID-19 patients. Conversely, drugs with poor lung distributions, including lopinavir/ritonavir, umifenovir and remdesivir, were insufficient to inhibit viral replication. Lopinavir/ritonavir might inhibit SARS-CoV-2 in the GI tract according to their distribution profiles. We concluded here that the antiviral drugs should be distributed straight to the lung tissue for reducing viral loads in respiratory tract of COVID-19 patients. Additionally, to better evaluate antiviral effects of drugs that target the intestine, the stool samples should also be collected for viral RNA test in the future. Twit Text FOAVip Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment ????Eur J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33031797 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33031797 #FOAvip English Wikipedia <ref>{{Cite pmid|33031797}}</ref> Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment #MMPMID33031797 Wang Y; Chen L Eur J Pharmacol 2020[Dec]; 889 (?): 173634 PMID33031797show ga Repurposing of approved antiviral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising strategy to treat Coronavirus disease 2019 (COVID-19) patients. Previously we reported our hypothesis that the antiviral drugs with high lung distributions might benefit COVID-19 patients by reducing viral loads. So far, chloroquine, lopinavir, hydroxychloroquine, azithromycin, favipiravir, ribavirin, darunavir, remdesivir, and umifenovir have been tested in COVID-19 clinical trials. Here we validated our hypothesis by comparing the pharmacokinetics profiles of these drugs and their capabilities of reducing viral load in clinical trials. According to bulk RNA and single cell RNA sequencing analysis, we found that high expression of both angiotensin converting enzyme 2 (ACE2) and transmembrane Serine Protease 2 (TMPRSS2) makes the lung and intestine vulnerable to SARS-CoV-2. Hydroxychloroquine, chloroquine, and favipiravir, which were highly distributed to the lung, were reported to reduce viral loads in respiratory tract of COVID-19 patients. Conversely, drugs with poor lung distributions, including lopinavir/ritonavir, umifenovir and remdesivir, were insufficient to inhibit viral replication. Lopinavir/ritonavir might inhibit SARS-CoV-2 in the GI tract according to their distribution profiles. We concluded here that the antiviral drugs should be distributed straight to the lung tissue for reducing viral loads in respiratory tract of COVID-19 patients. Additionally, to better evaluate antiviral effects of drugs that target the intestine, the stool samples should also be collected for viral RNA test in the future. |Angiotensin-Converting Enzyme 2/biosynthesis[MESH] |Antiviral Agents/*pharmacokinetics/*pharmacology[MESH] |COVID-19 Drug Treatment[MESH] |Humans[MESH] |Lung/metabolism[MESH] |Pandemics[MESH] |SARS-CoV-2/*drug effects[MESH] |Serine Endopeptidases/biosynthesis[MESH] |Tissue Distribution[MESH]Tissue distributions of antiviral drugs affect their capabilities of r(epmc).pdf DeepDyve Pubget Overpricing